Support for intensive statin therapy with recent MI

January 01, 0001

Support for intensive statin therapy with recent MI

Previous studies have demonstrated that benefits of intensive statin therapy compared to standard statin therapy begin shortly after an acute event and are continued up to 2 years of follow-up. However, whether efficacy and safety of intensive statin therapy in patients with a recent cardiac event are maintained in longer-term follow-up has not been evaluated. The researchers from Norway, Denmark, The Netherlands, Sweden, Finland and the US conducted a post hoc analysis of a subgroup of 999 patients who had a first acute myocardial infarction (MI) less than 2 months before randomization in a prospective, open-label, blinded end-point evaluation trial of 8,888 patients with a history of MI that compared intensive statin therapy (atorvastatin 80 mg) to standard statin therapy (simvastatin 20 to 40 mg) over approximately 5 years of follow-up. They analyzed the same composite end point used in the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) trial (death, MI, hospitalization for unstable angina, revascularization, and stroke).

Rates of the composite end point were 44.7% in the simvastatin group and 37.9% in the atorvastatin group (hazard ratio 0.82, significant). Although statistical power was smaller than that of the PROVE IT trial, the relative risk decrease observed at 5 years is consistent with that in the 2-year follow- up in PROVE IT. The 2 treatment regimens were well tolerated.

The researchers concluded: " … our analysis provides support for the strategy of placing patients with recent MI on intensive statin therapy and maintaining the high dose over the long term, beyond 2 years."

Can be balanced with other recent findings with regards to statins and we will need to look beyond two years.

For the full abstract, click here.

The American Journal of Cardiology 106(3):354-359, 1 August 2010 © 2010 Elsevier Inc
Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering {IDEAL} Trial). Terje R. Pedersen, Nilo B. Cater, Ole Faergeman et al. Correspondence to Terje Pedersen: [email protected]

Category: K. Circulatory. Keywords: atorvastatin, simvastatin, frequency, cardiovascular events, myocardial infarction, lipid, lowering, prospective, open- label, blinded end-point evaluation trial, journal watch.
Synopsis edited by Dr Stephen Wilkinson, Melbourne, Australia. Posted on Global Family Doctor 13 August 2010

Pearls are an independent product of the Cochrane primary care group and are meant for educational use and not to guide clinical care.